Endocrinology, Vol 136, 4174-4181, Copyright © 1995 by Endocrine Society

ARTICLES

Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block

NW Cheung and SC Boyages
Department of Clinical Endocrinology, Westmead Hospital, Sydney, Australia.

Somatostatin (SRIF) and its analogs exert potent inhibitory effects on hormonal hypersecretion. In addition, they have been demonstrated to inhibit the proliferation of various cell lines as well as the growth of some endocrine tumors in vivo. To evaluate the action of SRIF and its analog octreotide on the proliferation and cell cycle kinetics of endocrine cells, we investigated their effect on GH3 rat pituitary tumor cells, a GH-producing cell line. Using flow cytometric DNA analysis with propidium iodide staining, we found that octreotide inhibits the proliferation of synchronized GH3 cells, achieving a maximal reduction, compared to controls, of 19.4 +/- 5.3% and 22.4 +/- 5.1% with 100 ng/ml and 1000 ng/ml octreotide, respectively (P < 0.05). This effect was demonstrated to be due to a block in progression from the G0/G1 phase to the S phase of the cell cycle. This was most evident after 24 h of exposure to 100 ng/ml octreotide, at which time there was a 7.1 +/- 1.4% increase in cells in G0/G1 (P < 0.01) and a 6.6 +/- 1.3% decrease in cells in S phase (P < 0.01). However, unless octreotide was replenished, this effect was transient and overcome by 36-48 h. No apoptosis was seen, and trypan blue studies confirmed that cell death by necrosis did not occur. A single exposure to native SRIF-14 had little effect, but a G0/G1 cell cycle block and inhibition of proliferation were seen if SRIF was regularly replenished. We conclude that SRIF and octreotide exert a cytostatic effect on GH3 cells by causing a partial G0/G1 cell cycle block. These findings suggest that the actions of SRIF and octreotide occur through signal transduction pathways that act predominantly on downstream regulators.

This article has been cited by other articles:

				E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer, September 1, 2006; 13(3): 955 - 962. [Abstract] [Full Text] [PDF]

				E. Hubina, A. M Nanzer, M. R Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M. R. Terreni, S. Khalaf, S. Jordan, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol., August 1, 2006; 155(2): 371 - 379. [Abstract] [Full Text] [PDF]

				M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez-Pereda, C. Erneux, T. Florio, U. Pagotto, and G. K. Stalla Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression Cancer Res., February 1, 2006; 66(3): 1576 - 1582. [Abstract] [Full Text] [PDF]

				A. Massa, F. Barbieri, C. Aiello, S. Arena, A. Pattarozzi, P. Pirani, A. Corsaro, R. Iuliano, A. Fusco, G. Zona, et al. The Expression of the Phosphotyrosine Phosphatase DEP-1/PTP{eta} Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation J. Biol. Chem., July 9, 2004; 279(28): 29004 - 29012. [Abstract] [Full Text] [PDF]

				T. Florio, M. Morini, V. Villa, S. Arena, A. Corsaro, S. Thellung, M. D. Culler, U. Pfeffer, D. M. Noonan, G. Schettini, et al. Somatostatin Inhibits Tumor Angiogenesis and Growth via Somatostatin Receptor-3-Mediated Regulation of Endothelial Nitric Oxide Synthase and Mitogen-Activated Protein Kinase Activities Endocrinology, April 1, 2003; 144(4): 1574 - 1584. [Abstract] [Full Text] [PDF]

				M. Losa, E. Ciccarelli, P. Mortini, R. Barzaghi, D. Gaia, G. Faccani, M. Papotti, F. Mangili, M. R. Terreni, F. Camanni, et al. Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5194 - 5200. [Abstract] [Full Text] [PDF]

				E. Ballare, L. Persani, A. G. Lania, M. Filopanti, E. Giammona, S. Corbetta, S. Mantovani, M. Arosio, P. Beck-Peccoz, G. Faglia, et al. Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3809 - 3814. [Abstract] [Full Text] [PDF]

				D. C. Danila, J. N. S. Haidar, X. Zhang, L. Katznelson, M. D. Culler, and A. Klibanski Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2976 - 2981. [Abstract] [Full Text] [PDF]

				S. Charland, M.-J. Boucher, M. Houde, and N. Rivard Somatostatin Inhibits Akt Phosphorylation and Cell Cycle Entry, But Not p42/p44 Mitogen-Activated Protein (MAP) Kinase Activation in Normal and Tumoral Pancreatic Acinar Cells Endocrinology, January 1, 2001; 142(1): 121 - 128. [Abstract] [Full Text] [PDF]

				H. Baumeister, M. Wegner, D. Richter, and W. Meyerhof Dual Regulation Of Somatostatin Receptor Subtype 1 Gene Expression By Pit-1 In Anterior Pituitary GH3 Cells Mol. Endocrinol., February 1, 2000; 14(2): 255 - 271. [Abstract] [Full Text]

				P. Pages, N. Benali, N. Saint-Laurent, J.-P. Esteve, A. V. Schally, J. Tkaczuk, N. Vaysse, C. Susini, and L. Buscail sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27Kip1. EVIDENCE FOR THE ROLE OF SHP-1 J. Biol. Chem., May 21, 1999; 274(21): 15186 - 15193. [Abstract] [Full Text] [PDF]

				A. ALBINI, T. FLORIO, D. GIUNCIUGLIO, L. MASIELLO, S. CARLONE, A. CORSARO, S. THELLUNG, T. CAI, D. M. NOONAN, and G. SCHETTINI Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis FASEB J, April 1, 1999; 13(6): 647 - 655. [Abstract] [Full Text]

				T. Florio, H. Yao, K. D. Carey, T. J. Dillon, and P. J. S. Stork Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1) Mol. Endocrinol., January 1, 1999; 13(1): 24 - 37. [Abstract] [Full Text]

				K. Sharma, Y. C. Patel, and C. B. Srikant C-Terminal Region of Human Somatostatin Receptor 5 Is Required for Induction of Rb and G1 Cell Cycle Arrest Mol. Endocrinol., January 1, 1999; 13(1): 82 - 90. [Abstract] [Full Text]

				T. Florio, A. Scorziello, S. Thellung, S. Salzano, M. T. Berlingieri, A. Fusco, and G. Schettini Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity Endocrinology, September 1, 1997; 138(9): 3756 - 3763. [Abstract] [Full Text] [PDF]

				C. Benlot, L. Levy, P. Fontanaud, A. Roche, P. Rouannet, and D. Joubert Somatostatin and Growth Hormone-Releasing Hormone in Normal and Tumoral Human Breast Tissue: Endogenous Content, in Vitro Pulsatile Release, and Regulation J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 690 - 696. [Abstract] [Full Text] [PDF]